[Guidelines for usage of biological agents for treatment of rheumatoid arthritis].
作者信息
Takeuchi Tsutomu
机构信息
Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School.
出版信息
Nihon Rinsho. 2005 Jan;63 Suppl 1:444-7.
PMID:15799396
Abstract
摘要
相似文献
1
[Guidelines for usage of biological agents for treatment of rheumatoid arthritis].
Nihon Rinsho. 2005 Jan;63 Suppl 1:444-7.
2
[Infliximab for therapy of rheumatoid arthritis].
Nihon Rinsho. 2005 Jan;63 Suppl 1:517-20.
3
Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.
Rheumatology (Oxford). 2008 Jul;47(7):1097-9. doi: 10.1093/rheumatology/ken015a. Epub 2008 May 7.
4
Tumor necrosis factor-alpha blockade and the risk of vasculitis.
J Rheumatol. 2004 Oct;31(10):1885-7.
5
Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
Acta Derm Venereol. 2008;88(2):183-4. doi: 10.2340/00015555-0367.
6
Emerging biologic drugs for the treatment of rheumatoid arthritis.
Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016.
7
Rituximab (Rituxan) for rheumatoid arthritis.
Med Lett Drugs Ther. 2006 Apr 24;48(1233):34-5.
8
[TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
MMW Fortschr Med. 2002 May 16;144(20):65.
9
Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Arthritis Rheum. 2004 Apr 15;51(2):301-2. doi: 10.1002/art.20242.
10
Heart failure on infliximab.
Prescrire Int. 2002 Jun;11(59):86-7.
Zotero 插件